Skip to contentpdufa.bio

paxalisib Paxalisib

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

paxalisib Paxalisib is a KAZIA THERAPEUTICS LTD program in stage IV triple-negative breast cancer. Its next catalyst is a Readout in Q4 2027.

KZIA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Stage IV triple-negative breast cancer. Sponsor: KAZIA THERAPEUTICS LTD (KZIA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027KZIA

Questions

When is paxalisib Paxalisib's next FDA decision or readout?

The next tracked catalyst for paxalisib Paxalisib is a Readout in Q4 2027.

What happened at paxalisib Paxalisib's most recent FDA decision?

No FDA decision for paxalisib Paxalisib is in our archive yet.

What is paxalisib Paxalisib used for?

In our records paxalisib Paxalisib is under review or in development for Stage IV triple-negative breast cancer.

Who makes paxalisib Paxalisib?

KAZIA THERAPEUTICS LTD (KZIA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.